| Title |
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, July 2012
|
| DOI | 10.1007/s00280-012-1929-4 |
| Pubmed ID | |
| Authors |
Yosuke Togashi, Katsuhiro Masago, Satohiro Masuda, Tomoyuki Mizuno, Masahide Fukudo, Yasuaki Ikemi, Yuichi Sakamori, Hiroki Nagai, Young Hak Kim, Toshiya Katsura, Michiaki Mishima |
| Abstract |
Several cases have been reported in which central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC) resistant to gefitinib were improved by erlotinib. However, there has been no study in which cerebrospinal fluid (CSF) concentrations of gefitinib and erlotinib are directly compared. Thus, we aimed to compare them. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Unknown | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 99 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 1% |
| Unknown | 98 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 25 | 25% |
| Student > Ph. D. Student | 11 | 11% |
| Student > Bachelor | 10 | 10% |
| Student > Master | 8 | 8% |
| Student > Doctoral Student | 7 | 7% |
| Other | 21 | 21% |
| Unknown | 17 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 47 | 47% |
| Agricultural and Biological Sciences | 7 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 6% |
| Biochemistry, Genetics and Molecular Biology | 4 | 4% |
| Unspecified | 2 | 2% |
| Other | 8 | 8% |
| Unknown | 25 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 January 2015.
All research outputs
#16,899,948
of 24,849,927 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#1,894
of 2,544 outputs
Outputs of similar age
#109,786
of 168,636 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#16
of 19 outputs
Altmetric has tracked 24,849,927 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,544 research outputs from this source. They receive a mean Attention Score of 4.4. This one is in the 20th percentile – i.e., 20% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 168,636 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.